Akari Therapeutics Plc (AKTX) - Q3 2024 10-Q Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended September 30, 2024. Akari Therapeutics Plc is a biotechnology company focused on developing therapies for autoimmune and inflammatory diseases. The company operates as a non-accelerated filer and a smaller reporting company. As of the filing date, the company had completed a strategic merger with Peak Bio, Inc. (closed November 14, 2024), expanding its pipeline to include antibody drug conjugate (ADC) technologies.
Key Financial Metrics
| Metric | Q3 2024 (3 Months) | YTD 2024 (9 Months) | YTD 2023 (9 Months) |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Net Loss | $(2.9) million | $(16.0) million | $(5.9) million |
| Loss from Operations | $(2.9) million | $(16.4) million | $(11.7) million |
| Cash and Equivalents | $2.2 million (Sep 30, 2024) | Cash decreased $1.6 million YTD | |
| Operating Cash Flow | $(10.4) million used (YTD 2024) | $(12.0) million used (YTD 2023) | |
| Financing Cash Flow | $8.8 million provided (YTD 2024) | $3.5 million provided (YTD 2023) | |
| Total Assets | $2.7 million | Down from $4.4 million (Dec 31, 2023) | |
| Shareholders' Deficit | $(6.7) million | Accumulated deficit of $(243.5) million |
Material Changes vs. Prior Period
- Operating Expenses: Total operating expenses increased by $4.6 million YTD 2024 compared to YTD 2023. This increase was driven by Merger-related costs of $2.3 million and Restructuring costs of $1.7 million, which were not present in the prior year.
- Research & Development (R&D): R&D expenses increased $2.8 million YTD 2024 to $5.7 million. This reflects continued development of PAS-nomacopan and costs associated with the wind-down of the HSCT-TMA program, partially offset by a $1.3 million reduction in R&D expenses due to UK tax credits recognized in the period.
- General & Administrative (G&A): G&A expenses decreased by $2.2 million YTD 2024 to $6.6 million, primarily due to a 67% reduction-in-force (RIF) implemented in May 2024.
- Warrant Liability: The company recorded a non-cash gain of $0.5 million YTD 2024 from the change in fair value of warrant liabilities, compared to a $5.9 million gain in the prior year period.
Outlook, Risks, and Management Commentary
- Going Concern: Management has concluded there is substantial doubt about the company's ability to continue as a going concern for one year following the report date. Cash of $2.2 million is insufficient to fund operations for the next 12 months without additional financing.
- Liquidity Strategy: The company expects cash on hand plus proceeds from a November 2024 private placement ($3.2 million gross) to fund operations into the first quarter of 2025. Further equity or debt financing will be required.
- Merger Completion: The merger with Peak Bio closed on November 14, 2024. The combined entity will focus on Peak Bio's ADC platform and Akari's PAS-nomacopan for geographic atrophy (GA). The HSCT-TMA program was suspended in May 2024.
- Nasdaq Compliance: The company received a delisting determination in October 2024 for failing to meet the $2.5 million shareholders' equity requirement. However, on November 18, 2024, Nasdaq notified the company that it had regained compliance, and the scheduled hearing was canceled.
- Restructuring: A reduction-in-force of approximately 67% of the workforce was completed in Q3 2024 to reduce costs associated with the suspended HSCT-TMA program.
Investor Verification Checklist
- Cash Runway: Verify the closing of the November 2024 private placement and the actual cash proceeds received to confirm the runway into Q1 2025.
- Merger Integration: Monitor the integration of Peak Bio's assets and the impact on the combined balance sheet and future burn rate.
- Nasdaq Status: Confirm continued compliance with Nasdaq listing requirements, specifically the shareholders' equity threshold, given the recent volatility.
- Restructuring Accruals: Review the payment of accrued restructuring costs (approx. $0.5 million unpaid as of Sep 30) in Q4 2024.
- Convertible Notes: Note that $1.0 million in convertible notes issued to directors in May 2024 were partially converted and partially repaid in cash in October 2024.